Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00852345
Recruitment Status : No longer available
First Posted : February 27, 2009
Last Update Posted : April 3, 2015
Health Resources and Services Administration (HRSA)
Information provided by (Responsible Party):
Kaiser Permanente

February 26, 2009
February 27, 2009
April 3, 2015
Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy
Clofazimine has shown effectiveness in the treatment of leprosy for many years. The World Health Organization and the National Hansen's Disease Program consider clofazamine to be standard therapy for treatment of multibacillary leprosy. In recent years, the availability of the drug has become limited and is currently available only under a research protocol and is considered "investigational." Use of Clofazamine in patients presenting with lepromatous leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other therapies. This drug will be used prospectively for patients who require treatment of leprosy as deemed appropriate by a Kaiser Permanente Southern California physician.
Treatment protocol objective is to treat patients with clofazamine who meet inclusion criteria stated above.
Expanded Access
Drug: clofazamine
clofazamine 50mg po qday (duration varies according to physician)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
No longer available
Contact information is only displayed when the study is recruiting subjects
United States
Kaiser Permanente
Kaiser Permanente
Health Resources and Services Administration (HRSA)
Principal Investigator: Arnold M Henson, MD Kaiser Permanente
Kaiser Permanente
March 2015